CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
Ceribell Inc. ownership disclosure: FMR LLC reports beneficial ownership of 4,850,430.52 shares of Common Stock, representing 12.9% of the class, in an Amendment No. 3 to a Schedule 13G/A.
The filing states FMR LLC has 4,845,632 shares of sole voting power and 4,850,430.52 shares of sole dispositive power. The filing also notes that one or more other persons have rights to dividends or sale proceeds and refers to an attached 13d-1(k)(1) agreement.
Xingjuan Chao reports Rule 144 sales of Common stock. The filing lists sales of 2,084 shares on 02/23/2026 for $41,251.74, 39,000 shares on 03/03/2026 for $680,671.30, and 39,000 shares on 04/06/2026 for $717,550.46. The record also lists securities to be sold or exercised, including 39,000 shares associated with Fidelity Brokerage Services LLC and option-related entries dated 02/16/2023 and 09/25/2024.
Ceribell, Inc. Chief Technology Officer Raymond Woo reported an exercise-and-sell transaction in company stock. He exercised stock options covering a total of 11,104 shares of common stock at exercise prices of $4.70 and $2.24 per share, then sold 11,104 shares in open-market transactions at weighted average prices around $20.40 per share. According to the filing, these trades were carried out under a pre-arranged Rule 10b5-1 trading plan. Following the transactions, Woo directly holds 197,648 shares of Ceribell common stock.
CBLL submitted a Form 144 notice reporting proposed sales of Common Stock tied to option grants and recent open-market sales by Raymond Woo. The filing lists options granted on 07/07/2021 and 02/16/2023 with planned sales of 1,469 and 9,635 shares respectively, both with an 05/01/2026 sale date. The filing also discloses four sales by Raymond Woo during the prior three months: 11,112 shares on 02/02/2026 for $228,408.70, 705 shares on 02/23/2026 for $13,955.12, 11,112 shares on 03/02/2026 for $202,831.12, and 11,112 shares on 04/01/2026 for $206,260.79.
CeriBell, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 2, 2026 at 9:00 a.m. Pacific Time. Investors will elect two Class II directors, Josef Parvizi and Rebecca Robertson, to new three-year terms and ratify PricewaterhouseCoopers LLP as independent auditor for 2026.
Only holders of the 37,872,491 common shares outstanding as of April 6, 2026 may vote, either online during the meeting or by proxy in advance. The company outlines detailed governance practices, director and executive pay, related-party consulting with co‑founder Dr. Parvizi, and change‑in‑control severance protections for senior executives.
Ceribell, Inc. director and CEO Xingjuan Chao exercised stock options and sold shares in a planned trade. On April 6, 2026, she exercised options for 25,000 shares of Common Stock at $4.70 per share and sold 39,000 shares at a weighted average price of $18.40 per share pursuant to a Rule 10b5-1 trading plan. After these transactions, she holds 850,347 shares directly and 369,088 shares indirectly through the ACP 2021 Trust, where she is a co-trustee and disclaims beneficial ownership beyond her pecuniary interest.
CBLL: A Form 144 notice lists proposed and recent sales of Common stock by an affiliated holder. The filing shows proposed sales of 39,000 shares and earlier transactions including 39,000, 2,084, and 39,000 share entries with cash values recorded. Transactions are labeled as stock option exercises and issuer-related sales.
Ceribell, Inc. reported that President and CEO Chao Xingjuan received equity compensation awards. She was granted a stock option for 162,592 shares of common stock at an exercise price of $18.50 per share, expiring on April 1, 2036, vesting quarterly starting on May 20, 2026. She also received a grant of 97,555 shares of common stock in the form of restricted stock units. Following these awards, she directly holds 864,347 shares of common stock and has an additional 369,088 shares held indirectly through the ACP 2021 Trust, where she is a co-trustee and disclaims beneficial ownership except for her pecuniary interest.
Blumberg Scott reported acquisition or exercise transactions in this Form 4 filing.
Ceribell, Inc. Chief Financial Officer Scott Blumberg reported equity compensation awards. He received a stock option to buy 51,227 shares of common stock at $18.50 per share, expiring on April 1, 2036, and a grant of 30,736 restricted stock units. Following the common stock grant, his direct common stock holdings increased to 149,070 shares. The option shares vest on each quarterly anniversary from May 20, 2026, as long as he remains in an employment or service relationship with Ceribell, making these routine, service-based compensation awards rather than open-market purchases.